文献速递糖尿病

Tandem Control-IQ技术在成人1型糖尿病血糖管理与患者报告结局方面的一年真实世界获益:一项前瞻性观察性队列研究

One-year real-world benefits of Tandem Control-IQ technology on glucose management and person-reported outcomes in adults with type 1 diabetes: a prospective observational cohort study.
PubMed 文献 · Diabetologia · 2025-02-11

该多中心前瞻性观察性队列研究在13个比利时糖尿病中心连续纳入473例成人1型糖尿病患者,评估使用Control-IQ技术1年后血糖控制和患者报告结局的变化。使用12个月后,目标范围内时间从58.8%升至70.9%,HbA1c从57.3 mmol/mol降至49.5 mmol/mol,低血糖恐惧、糖尿病相关问题、治疗满意度均改善,严重低血糖和工作缺勤天数减少。

要点

  • 使用Control-IQ 12个月后目标范围内时间从58.8%升至70.9%,HbA1c从57.3降至49.5 mmol/mol。
  • 低于3.9 mmol/l时间从4.2%降至1.9%,自我报告严重低血糖事件从37.5降至15.7例/100人年。
  • 低血糖恐惧担忧评分、糖尿病问题简短量表评分降低,治疗满意度评分从25.5升至31.0分。

核心结论

  • 成人1型糖尿病患者使用Control-IQ 1年与更好的血糖管理、改善的糖尿病相关生活质量、更高的治疗满意度、更少的严重低血糖和更少的工作缺勤相关。

研究设计与样本

  • 多中心前瞻性观察性队列研究,2021年12月至2022年12月在13个比利时糖尿病中心连续纳入开始使用Control-IQ的成人1型糖尿病患者。
  • 共纳入473例成人,平均年龄38.5±13.1岁,女性占57.3%。
  • 在起始时及第4、8、12个月收集数据,主要终点为目标范围内时间(TIR;血糖3.9-10.0 mmol/l)的变化。
  • 数据以均值±标准差或最小二乘均值(95%CI)报告。
  • 试验注册号:ClinicalTrials.gov NCT04414280。

主要发现

  • TIR从起始时58.8%(95%CI 56.7,60.9)升至12个月时70.9%(69.1,72.8),p<0.001。
  • HbA1c从57.3 mmol/mol(56.1,58.5)(7.4% [7.3,7.5])降至49.5 mmol/mol(48.5,50.6)(6.7% [6.6,6.8]),低于3.9 mmol/l的时间从4.2%(3.9,4.6)降至1.9%(1.8,2.1),均p<0.001。
  • 低血糖恐惧调查第2版担忧评分从22.5分(21.3,23.7)降至18.1分(17.0,19.3),糖尿病问题简短量表评分从7.2分(6.7,7.8)降至6.1分(5.5,6.7),糖尿病治疗满意度问卷状态评分从25.5分(24.8,26.2)升至31.0分(30.4,31.6),均p<0.001。
  • 自我报告严重低血糖事件从37.5例/100人年(21.3,65.9)降至15.7例/100人年(9.7,25.3),p=0.002;工作缺勤天数从116.3天/100人年(42.8,315.5)降至69.3天/100人年(25.4,189.2),p=0.034。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: This multicentre prospective observational cohort study aimed to evaluate real-world changes in glycaemic and person-reported outcomes after 1 year's use of Control-IQ technology in adults with type 1 diabetes. METHODS: Adults who started with Control-IQ between December 2021 and December 2022 were consecutively recruited in 13 Belgian diabetes centres. Data were collected at start and after 4, 8 and 12 months. The primary endpoint was the evolution of time in range (TIR; glucose levels of 3.9-10.0 mmol/l). Data are reported as mean ± SD or least-squares mean (95% CI). RESULTS: A total of 473 adults were included, with a mean age of 38.5 ± 13.1 years and of whom 57.3% were female. TIR increased from 58.8% (95% CI 56.7, 60.9) at start to 70.9% (69.1, 72.8) at 12 months (p<0.001). HbA1c decreased from 57.3 mmol/mol (56.1, 58.5) (7.4% [7.3, 7.5]) to 49.5 mmol/mol (48.5, 50.6) (6.7% [6.6, 6.8]) and time <3.9 mmol/l from 4.2% (3.9, 4.6) to 1.9% (1.8, 2.1) (all p<0.001). Participants scored better on the Hypoglycaemia Fear Survey version 2 worry (22.5 [21.3, 23.7] vs 18.1 points [17.0, 19.3]), the Problem Areas in Diabetes - Short Form (7.2 [6.7, 7.8] vs 6.1 points [5.5, 6.7]), and the Diabetes Treatment Satisfaction Questionnaire status (25.5 [24.8, 26.2] vs 31.0 points [30.4, 31.6]) (all p<0.001). The number of self-reported severe hypoglycaemia events (37.5 [21.3, 65.9] vs 15.7 [9.7, 25.3] events per 100 person-years, p=0.002) and work absenteeism days (116.3 [42.8, 315.5] vs 69.3 [25.4, 189.2] days per 100 person-years, p=0.034) decreased. CONCLUSIONS/INTERPRETATION: One-year use of Control-IQ was associated with better glucose management, improved diabetes-related quality of life, more treatment satisfaction, less severe hypoglycaemia and less work absenteeism in adults with type 1 diabetes. TRIAL REGISTRATION: ClinicalTrials.gov NCT04414280.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. De Meulemeester J, Keymeulen B, De Block C, et al. One-year real-world benefits of Tandem Control-IQ technology on glucose management and person-reported outcomes in adults with type 1 diabetes: a prospective observational cohort study. Diabetologia. 2025. PMID: 39934368. doi:10.1007/s00125-025-06366-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。